Somatic genetic alterations in pituitary neuroendocrine tumors (PitNET) tissues have been identified in several studies, but detection of overlapping somatic PitNET candidate genes is rare. We sequenced and by employing multiple data analysis methods studied the exomes of 15 PitNET patients to improve discovery of novel factors involved in PitNET development. PitNET patients were recruited to the study before PitNET removal surgery. For each patient, two samples for DNA extraction were acquired: venous blood and PitNET tissue. Exome sequencing was performed using Illumina NexSeq 500 sequencer and data analyzed using two separate workflows and variant calling algorithms: GATK and Strelka2. A combination of two data analysis pipelines discovered 144 PitNET specific somatic variants (mean = 9.6, range 0-19 per PitNET) of which all were SNVs. Also, we detected previously known GNAS PitNET mutation and identified somatic variants in 11 genes, which have contained somatic variants in previous WES and WGS studies of PitNETs. Noteworthy, this is the third study detecting somatic variants in gene RYR1 in the exomes of PitNETs. In conclusion, we have identified two novel PitNET candidate genes (AC002519.6 and AHNAK) with recurrent somatic variants in our PitNET cohort and found 13 genes overlapping from previous PitNET studies that contain somatic variants. Our study demonstrated that the use of multiple sequencing data analysis pipelines can provide more accurate identification of somatic variants in PitNETs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417189PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265306PLOS

Publication Analysis

Top Keywords

somatic variants
28
pitnet
13
data analysis
12
somatic
9
exome sequencing
8
pituitary neuroendocrine
8
neuroendocrine tumors
8
pitnet candidate
8
candidate genes
8
pitnet patients
8

Similar Publications

Background: To date, mutations in the MAPT (i.e., tau) gene within Alzheimer's disease (AD) patients are either benign or have an unclear effect on pathogenicity.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Stanford University, School of Medicine, Stanford, CA, USA.

Background: Recently, clonal hematopoiesis of indeterminate potential (CHIP) was found to be associated with a reduced risk of Alzheimer's disease (AD) and somatic mutations found in the blood of CHIP carriers were also in microglia-enriched brain samples (Bouzid et al., 2023, Nature Medicine). We aimed to validate this finding in a larger dataset, explore the effect across APOE genotypes, and examine the association of CHIP with age-at-onset.

View Article and Find Full Text PDF

Background: Ovarian Cancer is one of the leading causes of cancer death among women worldwide and the therapeutic landscape to treat it is constantly evolving. One of the major points of decision for the treatment choice is the presence of some genomic alterations that could confer sensitivity to the new available therapies including inhibitors of poly (ADP-ribose) polymerase (PARPi) with BRCA1 and 2 genes playing the most important role.

Methods And Results: We performed the search for any somatic and/or germline alteration in patient's samples by next generation sequencing (NGS).

View Article and Find Full Text PDF

Mutation impact on mRNA versus protein expression across human cancers.

Gigascience

January 2025

Department of Genetics and Genomic Sciences, Department of Artificial Intelligence and Human Health, Center for Transformative Disease Modeling, Tisch Cancer Institute, Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Background: Cancer mutations are often assumed to alter proteins, thus promoting tumorigenesis. However, how mutations affect protein expression-in addition to gene expression-has rarely been systematically investigated. This is significant as mRNA and protein levels frequently show only moderate correlation, driven by factors such as translation efficiency and protein degradation.

View Article and Find Full Text PDF

FMS-like tyrosine kinase 3 (FLT3) genetic variants are commonly seen in high-grade myeloid neoplasms and are typically gain-of-function mutations associated with a proliferative disease phenotype. Inactivating FLT3 variants have been less frequently described in non-malignant, autoimmune disorders and are uncommon in aplastic anemia (AA). Herein, we report the first to our knowledge, and unusual case of a germline, gain-of-function, FLT3 variant in a patient with severe AA treated successfully with immunosuppressive therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!